Logo image of SRDX

SURMODICS INC (SRDX) Stock Fundamental Analysis

NASDAQ:SRDX - Nasdaq - US8688731004 - Common Stock - Currency: USD

28.76  -0.25 (-0.86%)

Fundamental Rating

3

SRDX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. While SRDX seems to be doing ok healthwise, there are quite some concerns on its profitability. SRDX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SRDX has reported negative net income.
In the past year SRDX has reported a negative cash flow from operations.
In multiple years SRDX reported negative net income over the last 5 years.
Of the past 5 years SRDX 4 years had a positive operating cash flow.
SRDX Yearly Net Income VS EBIT VS OCF VS FCFSRDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

1.2 Ratios

SRDX's Return On Assets of -12.17% is in line compared to the rest of the industry. SRDX outperforms 58.82% of its industry peers.
Looking at the Return On Equity, with a value of -18.02%, SRDX is in the better half of the industry, outperforming 62.57% of the companies in the same industry.
Industry RankSector Rank
ROA -12.17%
ROE -18.02%
ROIC N/A
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
SRDX Yearly ROA, ROE, ROICSRDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

SRDX's Gross Margin of 73.37% is amongst the best of the industry. SRDX outperforms 85.03% of its industry peers.
In the last couple of years the Gross Margin of SRDX has declined.
SRDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
SRDX Yearly Profit, Operating, Gross MarginsSRDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

SRDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRDX has been increased compared to 1 year ago.
Compared to 5 years ago, SRDX has more shares outstanding
The debt/assets ratio for SRDX is higher compared to a year ago.
SRDX Yearly Shares OutstandingSRDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
SRDX Yearly Total Debt VS Total AssetsSRDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 6.36 indicates that SRDX is not in any danger for bankruptcy at the moment.
SRDX has a better Altman-Z score (6.36) than 83.96% of its industry peers.
SRDX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.27, SRDX perfoms like the industry average, outperforming 50.27% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 6.36
ROIC/WACCN/A
WACC8.93%
SRDX Yearly LT Debt VS Equity VS FCFSRDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.14 indicates that SRDX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.14, SRDX is in the better half of the industry, outperforming 75.94% of the companies in the same industry.
SRDX has a Quick Ratio of 3.99. This indicates that SRDX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.99, SRDX is doing good in the industry, outperforming 73.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.14
Quick Ratio 3.99
SRDX Yearly Current Assets VS Current LiabilitesSRDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

SRDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -150.89%.
Looking at the last year, SRDX shows a very negative growth in Revenue. The Revenue has decreased by -14.96% in the last year.
Measured over the past years, SRDX shows a small growth in Revenue. The Revenue has been growing by 4.72% on average per year.
EPS 1Y (TTM)-150.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-285.71%
Revenue 1Y (TTM)-14.96%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-12.12%

3.2 Future

The Earnings Per Share is expected to grow by 42.04% on average over the next years. This is a very strong growth
SRDX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.17% yearly.
EPS Next Y-71.24%
EPS Next 2Y10.29%
EPS Next 3Y42.04%
EPS Next 5YN/A
Revenue Next Year-6.59%
Revenue Next 2Y-1.58%
Revenue Next 3Y1.17%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRDX Yearly Revenue VS EstimatesSRDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
SRDX Yearly EPS VS EstimatesSRDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRDX Price Earnings VS Forward Price EarningsSRDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

SRDX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SRDX is cheaper than 62.57% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 91.13
SRDX Per share dataSRDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as SRDX's earnings are expected to grow with 42.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.29%
EPS Next 3Y42.04%

More info and screens

0

5. Dividend

5.1 Amount

SRDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURMODICS INC

NASDAQ:SRDX (6/25/2025, 2:24:42 PM)

28.76

-0.25 (-0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners84.09%
Inst Owner Change2.47%
Ins Owners3.36%
Ins Owner Change0.6%
Market Cap411.27M
Analysts77.78
Price Target43.86 (52.5%)
Short Float %2.96%
Short Ratio5.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.11%
Min EPS beat(2)-12.46%
Max EPS beat(2)66.67%
EPS beat(4)3
Avg EPS beat(4)32.66%
Min EPS beat(4)-12.46%
Max EPS beat(4)66.67%
EPS beat(8)7
Avg EPS beat(8)175.9%
EPS beat(12)11
Avg EPS beat(12)125.99%
EPS beat(16)15
Avg EPS beat(16)104.28%
Revenue beat(2)0
Avg Revenue beat(2)-13.33%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)-12.08%
Revenue beat(4)1
Avg Revenue beat(4)-5.09%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)7.17%
Revenue beat(8)5
Avg Revenue beat(8)3.61%
Revenue beat(12)8
Avg Revenue beat(12)2.97%
Revenue beat(16)11
Avg Revenue beat(16)2.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-94.67%
EPS NY rev (1m)-1.47%
EPS NY rev (3m)-49.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.38
P/FCF N/A
P/OCF N/A
P/B 3.73
P/tB 9.04
EV/EBITDA 91.13
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS8.5
BVpS7.71
TBVpS3.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.17%
ROE -18.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.37%
FCFM N/A
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
F-Score2
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA 6.56
Cap/Depr 25%
Cap/Sales 1.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.14
Quick Ratio 3.99
Altman-Z 6.36
F-Score2
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)37.09%
Cap/Depr(5y)48.03%
Cap/Sales(3y)2.78%
Cap/Sales(5y)3.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-150.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-285.71%
EPS Next Y-71.24%
EPS Next 2Y10.29%
EPS Next 3Y42.04%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.96%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-12.12%
Revenue Next Year-6.59%
Revenue Next 2Y-1.58%
Revenue Next 3Y1.17%
Revenue Next 5YN/A
EBIT growth 1Y-120.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year181.27%
EBIT Next 3Y61.29%
EBIT Next 5YN/A
FCF growth 1Y71.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.48%
OCF growth 3Y-74.74%
OCF growth 5Y-50.13%